| Literature DB >> 35019033 |
Duyan Geng1,2, Yan Wang2, Zeyu Gao2, Jiaxing Wang2, Xuanyu Liu2, Geng Pang2.
Abstract
Alzheimer's disease (AD) is one of the most common neurodegenerative diseases in the elderly. The aim of this study was to explore the effects of AD on cardiac function and autonomic nervous function, and the feasibility of electrocardiogram (ECG) in monitoring the development of AD. APP/PS1 double transgenic mice were used in the Morris water maze (MWM) experiment to evaluate the changes of cognitive ability of AD mice, then the non-invasive ECG acquisition system was used and the changes of ECG intervals and heart rate variability (HRV) were analyzed. AD mice already had cognitive dysfunction at the age of 5 months, reaching the level of mild dementia, and the degree of dementia increased with the course of disease. There were no significant changes in ECG intervals in the AD group at each month. The mean square of successive RR interval differences, percentage of intervals >6 ms different from preceding interval, and normalized high frequency power component in the AD group were decreased and low-to-high frequency power ratio and normalized low frequency power component were increased. Combined with the results of the MWM, it was shown that the regulation mechanism of sympathetic and parasympathetic nerves in mice was already imbalanced in early stage AD, which was manifested as the increase of excessive activity of sympathetic nerves and the inhibition of parasympathetic activities. Therefore, ECG-based analysis of HRV may become a means of daily monitoring of AD and provide an auxiliary basis for clinical diagnosis.Entities:
Mesh:
Year: 2022 PMID: 35019033 PMCID: PMC8851908 DOI: 10.1590/1414-431X2021e11504
Source DB: PubMed Journal: Braz J Med Biol Res ISSN: 0100-879X Impact factor: 2.590
Mean escape latency of Alzheimer’s disease (AD) and wild type (WT) mice of different ages.
| Day of training/Group | 5 months old | 7 months old | 10 months old | 12 months old |
|---|---|---|---|---|
| Day 1 | ||||
| AD | 50.22±5.25 | 54.44±6.56 | 56.73±2.67 | 59.29±1.22 |
| WT | 38.34±4.09 | 53.56±6.54 | 46.03±4.61 | 51.34±7.10 |
| P | 0.764 | 0.957 | 0.887 | 0.974 |
| Day 2 | ||||
| AD | 38.89±4.47 | 38.23±9.68 | 58.27±1.73 | 55.74±1.56 |
| WT | 36.56±3.76 | 29.16±4.55 | 45.01±4.66 | 46.7±7.5 |
| P | 0.893 | 0.773 | 0.594 | 0.536 |
| Day 3 | ||||
| AD | 27.73±4.48 | 35.96±6.9 | 43.07±6.24 | 54.19±6.88 |
| WT | 16.08±2.52 | 17.15±3.53 | 18.45±3.83 | 24.99±3.94 |
| P | 0.047* | 0.044* | 0.035* | 0.028* |
| Day 4 | ||||
| AD | 29.85±4.32 | 30.43±3.68 | 36.55±6.33 | 43.55±1.19 |
| WT | 19.54±2.94 | 12.93±3.65 | 16.87±3.39 | 10.18±4.16 |
| P | 0.022* | 0.017* | 0.033* | 0.014* |
| Day 5 | ||||
| AD | 17.56±2.73 | 24.13±4.77 | 26.43±6.00 | 38.98±4.19 |
| WT | 12.85±1.67 | 10.24±3.04 | 15.10±2.08 | 10.92±3.39 |
| P | 0.012* | <0.001** | 0.025* | <0.001** |
| Day 6 | ||||
| AD | 17.92±3.83 | 24.84±3.34 | 28.54±5.84 | 35.83±6.98 |
| WT | 12.73±1.78 | 9.79±2.77 | 17.57±3.61 | 10.97±2.7 |
| P | 0.035* | 0.027* | 0.013* | <0.001** |
Data are reported as means±SE (n=10/group). AD: APP/PS1 double transgenic mice; WT: C57BL/6J wild type mice. *P<0.05, **P<0.01, AD groups compared to WT groups at days 1 to 6 of training (t-test).
Figure 1A, Heart rate (HR); B, PR interval; C, QRS interval duration; and D, QT dispersion (QTd) of Alzheimer’s disease (AD) and wild type (WT) mice of different ages. Data are reported as means±SE (n=10/group). AD: APP/PS1 double transgenic mice; WT: C57BL/6J wild type mice.
Figure 2A, The square root of the mean of the squares of successive RR interval differences (RMSSD); B, percentage of intervals >6 ms different from preceding interval (PNN6) of Alzheimer’s disease (AD) and wild type (WT) mice of different ages. Data are reported as means±SE (n=10/group). AD: APP/PS1 double transgenic mice; WT: C57BL/6J wild type mice. *P<0.05 (t-test).
Figure 3A, The ratio of low frequency power to high frequency power (LF/HF); B, normalized low frequency power component (LFn); and C, normalized high frequency power component (HFn) of Alzheimer’s disease (AD) and wild type (WT) mice of different ages. Data are reported as means±SE (n=10/group). AD: APP/PS1 double transgenic mice; WT: C57BL/6J wild type mice. *P<0.05; **P<0.01 (t-test).